Modeling the Public Health Impact of Improved Antiretroviral Therapy Restart Patterns Among People with HIV Who Have Discontinued Treatment.

IF 2.3 Q2 ECONOMICS
Journal of Health Economics and Outcomes Research Pub Date : 2026-03-26 eCollection Date: 2026-01-01 DOI:10.36469/001c.159112
Hansel E Tookes, Cillian Copeland, Uche Mordi, James Jarrett, Rui Martins, Mark Connolly, Patrick S Sullivan
{"title":"Modeling the Public Health Impact of Improved Antiretroviral Therapy Restart Patterns Among People with HIV Who Have Discontinued Treatment.","authors":"Hansel E Tookes, Cillian Copeland, Uche Mordi, James Jarrett, Rui Martins, Mark Connolly, Patrick S Sullivan","doi":"10.36469/001c.159112","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Antiretroviral therapy (ART) has become a cornerstone of human immunodeficiency virus (HIV) management. However, a challenge in HIV care and policy is ensuring individuals remain engaged in care and on treatment over time. Discontinuation of ART is common for various reasons, and prolonged treatment interruptions can lead to worse health outcomes at the individual level and increased HIV transmissions at the public health level.</p><p><strong>Objective: </strong>A cost-consequence analysis was conducted to evaluate the economic and public health impact of reducing the interval to ART restart among people with HIV (PWH) who have disengaged from care.</p><p><strong>Methods: </strong>A state transition disease model was developed to calculate the economic benefits from improving treatment restart patterns from a United States healthcare payer perspective. Two hypothetical cohorts of 1000 PWH who discontinued ART were compared: a standard-of-care cohort where restart occurs 32 weeks after discontinuation, and a comparator cohort exploring the impact of reducing the time between ART discontinuation and restart to 12 weeks. Individuals were assigned to CD4-related health states, and rates of viral suppression were considered. Four outcomes, ART costs, CD4 health state costs, CD4-related mortality, and new HIV transmissions were calculated over a three-year time horizon. Cost savings from averted HIV cases were valued based on the lifetime excess healthcare costs for a PWH.</p><p><strong>Results: </strong>Increasing the proportion of individuals restarting ART and reducing time to restart was estimated to avert 88 HIV transmissions. This corresponds to a number needed to treat, defined as the number of PWH who would need to experience the earlier restart pattern of the comparator cohort, of 11 to avoid one new transmission, and $101 083 857 lifetime cost savings. Cost savings attributable to improved CD4 counts in the cohort were also found.</p><p><strong>Conclusion: </strong>Enhancing ART restart patterns improves health and provides considerable cost savings by improving individuals' CD4 counts and reducing new HIV transmissions from people who are viremic. Effective policies to promote care engagement and treatment adherence are predicted to improve the health of PWH and reduce new HIV cases.</p>","PeriodicalId":16012,"journal":{"name":"Journal of Health Economics and Outcomes Research","volume":"13 1","pages":"103-110"},"PeriodicalIF":2.3000,"publicationDate":"2026-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13032768/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Health Economics and Outcomes Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.36469/001c.159112","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"ECONOMICS","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Antiretroviral therapy (ART) has become a cornerstone of human immunodeficiency virus (HIV) management. However, a challenge in HIV care and policy is ensuring individuals remain engaged in care and on treatment over time. Discontinuation of ART is common for various reasons, and prolonged treatment interruptions can lead to worse health outcomes at the individual level and increased HIV transmissions at the public health level.

Objective: A cost-consequence analysis was conducted to evaluate the economic and public health impact of reducing the interval to ART restart among people with HIV (PWH) who have disengaged from care.

Methods: A state transition disease model was developed to calculate the economic benefits from improving treatment restart patterns from a United States healthcare payer perspective. Two hypothetical cohorts of 1000 PWH who discontinued ART were compared: a standard-of-care cohort where restart occurs 32 weeks after discontinuation, and a comparator cohort exploring the impact of reducing the time between ART discontinuation and restart to 12 weeks. Individuals were assigned to CD4-related health states, and rates of viral suppression were considered. Four outcomes, ART costs, CD4 health state costs, CD4-related mortality, and new HIV transmissions were calculated over a three-year time horizon. Cost savings from averted HIV cases were valued based on the lifetime excess healthcare costs for a PWH.

Results: Increasing the proportion of individuals restarting ART and reducing time to restart was estimated to avert 88 HIV transmissions. This corresponds to a number needed to treat, defined as the number of PWH who would need to experience the earlier restart pattern of the comparator cohort, of 11 to avoid one new transmission, and $101 083 857 lifetime cost savings. Cost savings attributable to improved CD4 counts in the cohort were also found.

Conclusion: Enhancing ART restart patterns improves health and provides considerable cost savings by improving individuals' CD4 counts and reducing new HIV transmissions from people who are viremic. Effective policies to promote care engagement and treatment adherence are predicted to improve the health of PWH and reduce new HIV cases.

在停止治疗的艾滋病毒感染者中改进抗逆转录病毒治疗重新开始模式的公共卫生影响建模
背景:抗逆转录病毒治疗(ART)已成为人类免疫缺陷病毒(HIV)管理的基石。然而,艾滋病毒护理和政策方面的一个挑战是确保个人长期参与护理和治疗。由于各种原因,停止抗逆转录病毒治疗是很常见的,长期中断治疗可能导致个人健康结果恶化,并增加公共卫生层面的艾滋病毒传播。目的:进行成本-后果分析,以评估缩短已脱离护理的艾滋病毒感染者(PWH)重新开始抗逆转录病毒治疗的间隔时间对经济和公共卫生的影响。方法:建立状态转移疾病模型,从美国医疗保健支付者的角度计算改善治疗重启模式的经济效益。两个假设的1000名停止抗逆转录病毒治疗的PWH队列进行了比较:一个是标准护理队列,在停药32周后重新开始治疗,另一个是比较队列,探索将停止抗逆转录病毒治疗和重新开始治疗之间的时间缩短到12周的影响。个体被分配到与cd4相关的健康状态,并考虑病毒抑制率。在三年的时间范围内计算了四种结果,即抗逆转录病毒治疗费用、CD4健康状态费用、CD4相关死亡率和新的艾滋病毒传播。避免艾滋病毒病例所节省的成本是根据PWH的终身超额医疗费用来评估的。结果:估计增加重新开始抗逆转录病毒治疗的个体比例并减少重新开始治疗的时间可避免88例艾滋病毒传播。这相当于需要治疗的人数(定义为需要经历比较队列较早重启模式的PWH人数)为11人以避免一次新的传播,并节省101 083 857美元的终身成本。在队列中,由于CD4计数的提高而节省的成本也被发现。结论:加强抗逆转录病毒治疗的重启模式可以改善健康状况,并通过改善个人CD4计数和减少病毒感染者的新艾滋病毒传播,节省大量费用。预计促进护理参与和治疗依从性的有效政策将改善PWH的健康状况并减少新的艾滋病毒病例。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
3.00
自引率
0.00%
发文量
55
审稿时长
10 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书